Clinical Trials
8 trialsNCT06287944 2026-05-18
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
City of Hope Medical Center
Phase 1 Recruiting
NCT06996119 2026-05-11
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
City of Hope Medical Center
Phase 1 Recruiting
NCT04375631 2026-03-05
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Fred Hutchinson Cancer Center
Phase 1 Recruiting
NCT04521946 2024-10-26
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT02484391 2024-09-19
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma
Wake Forest University Health Sciences
Phase 1 Completed
NCT00424489 2018-08-31
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
Northwestern University
Phase 1 Terminated
NCT00824135 2017-01-02
Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00278486 2013-04-08
Hematopoietic Stem Cell Transplantation in Autoimmune-Related Retinopathy(ARRON)
Northwestern University
Phase 1 Terminated